Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Piritrexim (ILEX Oncology).

J A Fraser1, J Bartlett

  • 1Department of Medical Oncology, Glasgow Royal Infirmary, Glasgow, UK. gqva20@udcf.gla.ac.uk

Idrugs : the Investigational Drugs Journal
|August 23, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impacts of a Clinical Quality Registry on Lung Cancer Quality Measures: A Retrospective Observational Study of the Victorian Lung Cancer Registry.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025
Same author

PHOMS: An apt and accurate acronym.

Archivos de la Sociedad Espanola de Oftalmologia·2024
Same author

White cord syndrome.

ANZ journal of surgery·2023
Same author

Search for Subsolar-Mass Binaries in the First Half of Advanced LIGO's and Advanced Virgo's Third Observing Run.

Physical review letters·2022
Same author

Corrigendum to: 1292 Aortic Valve Neocuspidization Using Glutaraldehyde-Treated Autologous Pericardium: A Literature Review.

The British journal of surgery·2022
Same author

Point Absorber Limits to Future Gravitational-Wave Detectors.

Physical review letters·2021
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Piritrexim, a dihydrofolate reductase inhibitor, showed promising tumor responses in various cancers, including bladder cancer. However, development was discontinued for bladder cancer due to lack of efficacy.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Piritrexim, a dihydrofolate reductase inhibitor, was developed by Burroughs Wellcome and later licensed by ILEX Oncology.
  • It was investigated for its potential efficacy in various cancers, including methotrexate-resistant tumors.

Purpose of the Study:

  • To evaluate the efficacy and safety of piritrexim in cancer patients.
  • To explore piritrexim's potential as a treatment for advanced bladder cancer, AIDS-related Kaposi's sarcoma, and other malignancies.

Main Methods:

  • Phase II and III clinical trials were conducted in the US and Europe.
  • Studies involved patients with advanced bladder cancer, malignant fibrous histiocytoma, and AIDS-related Kaposi's sarcoma.

Main Results:

  • Piritrexim demonstrated objective response rates of 23-75% in advanced bladder cancer patients who failed first-line chemotherapy.

Related Experiment Videos

  • Tumor responses were observed in patients with bladder cancer, Kaposi's sarcoma, colon cancer, melanoma, and head and neck cancer.

    • Conclusions:

    • Piritrexim showed potential in treating various cancers, particularly bladder cancer.
    • Development for bladder cancer was discontinued due to lack of efficacy; further development for other indications is unclear.